Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039796 | 0.90 | MTNR1A (0.48) | L3MBTL1DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL7037275 | 0.81 | DRD2 (0.45) | GAAL3MBTL1HCRTR1TSHRDRD2 | |
| SCHEMBL7669210 | 0.80 | GAA (0.48) | GAAL3MBTL1DRD2DRD3HSD17B10 | |
| SCHEMBL7669208 | 0.80 | GAA (0.48) | GAAL3MBTL1DRD2DRD3HSD17B10 | |
| SCHEMBL12596308 | 0.78 | DRD2 (0.48) | GAAL3MBTL1TSHRDRD2DRD3 | |
| SCHEMBL7036768 | 0.77 | MEN1 (0.43) | ALDH1A1MTNR1APRCPHPGDKMT2A | |
| Benzene SCHEMBL27790053 | 0.77 | DRD2 (0.47) | GAATSHRDRD2DRD3KDM4E | |
| SCHEMBL7044762 | 0.77 | MAPT (0.54) | GAATSHRDRD2DRD3KDM4E | |
| Benzene SCHEMBL27768484 | 0.73 | MAPT (0.46) | GAADRD2DRD3ALDH1A1HSD17B10 | |
| SCHEMBL7042289 | 0.71 | NPC1 (0.45) | GAADRD2DRD3SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | INSERM | 2003-02-06 | — | — | US | disclosed |
| US-6403561-B1 | DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | DPP4, DPP3, DPP9 | GAA 67/4885L3MBTL1 1017/4885HCRTR1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.